INCY - Earnings announcements

- Proposed acquisition to add VGA039, a novel investigational monoclonal antibody that targets Protein S in Phase 3 development for von Willebrand disease (VWD) - Star Therapeutics to receive $1.25 billion upfront, with up to $750 million in additional payments upon achievement of sales milestones - Incyte will host an analyst and investor call on Monday, June 8, 2026, at 8:00 a.m. ET Incyte (NASDAQ:INCY) announced today it has entered into a definitive agreement to acquire Vega Therapeutics, Inc., a wholly owned subsidiary of Star Therapeutics, LLC, for $1.25 billion. Star Therapeutics will be eligible to receive up to $750 million in additional payments upon the achievement of sales

Total revenue of $1.27 billion and total net sales of $1.10 billion in the first quarter of 2026, an increase of 21% and 20% respectively, compared to the first quarter of 2025 Jakafi® (ruxolitinib) net sales of $758 million, an increase of 7% compared to the same period in 2025 Opzelura® (ruxolitinib) cream net sales of $143 million and Hematology and Oncology portfolio net sales of $204 million, an increase of 20% and 116%, respectively, compared to the first quarter of 2025 Four anticipated approvals and launches from mid-2026 into early 2027 Advanced povorcitinib development program, including the New Drug Application (NDA) acceptance in hidradenitis suppurativa (HS) and positiv

Incyte (NASDAQ:INCY) announced today that it has scheduled its first quarter financial results conference call and webcast for 8:00 a.m. ET on Tuesday, April 28, 2026. The schedule for the press release and conference call/webcast is as follows: Q1 2026 Press Release: April 28, 2026 at 7:00 a.m. ET Q1 2026 Conference Call: April 28, 2026 at 8:00 a.m. ET Domestic Dial-In Number: 877-407-3042 International Dial-In Number: 201-389-0864 Conference ID Number: 13759527 If you are unable to participate, a replay of the conference call will be available for thirty days. The replay dial-in number for the U.S. is 877-660-6853 and the dial-in number for international callers is 201

Total revenue of $1.51 billion (+28% Y/Y) in the fourth quarter 2025 and $5.14 billion (+21% Y/Y) for the full year 2025 Total net product revenue of $1.22 billion (+20% Y/Y) in the fourth quarter 2025 and $4.35 billion (+20%) for the full year 2025, exceeding full year 2025 net product revenue guidance of $4.23 - $4.32 billion Provides full year 2026 total net product revenue guidance range of $4.77 - $4.94 billion Conference Call and Webcast Scheduled Today at 8:00 a.m. ET Incyte (NASDAQ:INCY) today announced financial results for the fourth quarter and full year ended December 31, 2025 and provided full year 2026 financial guidance. "Our fourth quarter and full year 2025 result

Incyte (NASDAQ:INCY) announced today that it has scheduled its fourth quarter and year-end 2025 financial results conference call and webcast for 8:00 a.m. ET on Tuesday, February 10, 2026. The schedule for the press release and conference call/webcast is as follows: Q4 & YE 2025 Press Release: February 10, 2026 at 7:00 a.m. ET Q4 & YE 2025 Conference Call: February 10, 2026 at 8:00 a.m. ET Domestic Dial-In Number: 877-407-3042 International Dial-In Number: 201-389-0864 Conference ID Number: 13758313 If you are unable to participate, a replay of the conference call will be available for thirty days. The replay dial-in number for the U.S. is 877-660-6853 and the dial-in n

Rapid and robust reductions in spleen volume and symptoms, and improvements in anemia were observed with INCA033989 as monotherapy and in combination with ruxolitinib (Jakafi®) in patients with myelofibrosis (MF) harboring a CALR mutation (mutCALR) Results demonstrate a favorable safety profile for INCA033989 as a monotherapy and in combination with ruxolitinib – no dose limiting toxicities were reported and a maximum tolerated dose was not reached A reduction in peripheral blood mutCALR variant allele frequency (VAF) from baseline was observed in MF patients in the INCA033989 monotherapy arm with ≥1 post-baseline VAF measurement Exploratory analyses from the clinical studies of INCA

INCA033989, a first-in-class mutant calreticulin (mutCALR)-targeted monoclonal antibody, will be showcased in three presentations, including new Phase 1 monotherapy and combination data in myelofibrosis (MF), updated data in essential thrombocythemia (ET) and translational data demonstrating disease modifying activity in both ET and MF. Additionally, the more than 50 abstracts accepted at ASH include new and updated data from Incyte's MPN, GVHD and hematology programs including interim safety data evaluating axatilimab (Niktimvo™) in combination with ruxolitinib in GVHD Incyte to host an investor event and webcast highlighting the mutCALR data from the oral presentation at ASH on

Total revenues of $1.37 billion in the third quarter of 2025, reflecting 20% growth compared to the third quarter of 2024 Jakafi® (ruxolitinib) net product revenue of $791 million, an increase of 7% compared to the same period in 2024 Opzelura® (ruxolitinib) cream net product revenue of $188 million, an increase of 35% compared to the prior year period Hematology-Oncology portfolio net product revenues of $171 million, including Niktimvo™ (axatilimab-csfr) net revenue of $46 million Raises 2025 full year net product revenue guidance to $4.23 - $4.32 billion Conference Call and Webcast Scheduled Today at 8:00 a.m. ET Incyte (NASDAQ:INCY) today reported financial results for the t

Incyte (NASDAQ:INCY) announced today that it has scheduled its third quarter financial results conference call and webcast for 8:00 a.m. ET on Tuesday, October 28, 2025. The schedule for the press release and conference call/webcast is as follows: Q3 2025 Press Release: October 28, 2025 at 7:00 a.m. ET Q3 2025 Conference Call: October 28, 2025 at 8:00 a.m. ET Domestic Dial-In Number: 877-407-3042 International Dial-In Number: 201-389-0864 Conference ID Number: 13756261 If you are unable to participate, a replay of the conference call will be available for thirty days. The replay dial-in number for the U.S. is 877-660-6853 and the dial-in number for international callers

– Total revenues of $1,216 million in the second quarter (Q2'25) (+16% Y/Y); total product revenues of $1,059 million in Q2'25 (+17%Y/Y) – Jakafi® (ruxolitinib) net product revenues of $764 million in Q2'25 (+8% Y/Y); raising full year 2025 guidance to a new range of $3,000 - $3,050 million [previously $2,950 - $3,000 million] – Opzelura® (ruxolitinib) cream net product revenues of $164 million in Q2'25 (+35% Y/Y) – Niktimvo™ (axatilimab-csfr) net product revenues of $36 million in the second quarter, demonstrating strong commercial execution; raising full year 2025 Other Oncology guidance to a new range of $500 - $520 million [previously $415 - $455 million] – Zynyz® (retifanlimab-

Incyte (NASDAQ:INCY) announced today that it has scheduled its second quarter financial results conference call and webcast for 8:00 a.m. ET on Tuesday, July 29, 2025. The schedule for the press release and conference call/webcast is as follows: Q2 2025 Press Release: July 29, 2025 at 7:00 a.m. ET Q2 2025 Conference Call: July 29, 2025 at 8:00 a.m. ET Domestic Dial-In Number: 877-407-3042 International Dial-In Number: 201-389-0864 Conference ID Number: 13754581 If you are unable to participate, a replay of the conference call will be available for thirty days. The replay dial-in number for the U.S. is 877-660-6853 and the dial-in number for international callers is 201-6

Data demonstrates the potential for INCA033989 to modify disease by directly inhibiting and eliminating oncogenic mutCALR cells, while sparing healthy cells and restoring normal blood cell production In high-risk patients with essential thrombocythemia (ET) with a CALR mutation (mutCALR), 86% of INCA033989-treated patients at doses 400 mg and above achieved a complete or partial hematologic response with the majority (82%) realizing a complete response A reduction in peripheral blood mutCALR variant allele frequency (VAF) was observed in 89% of evaluable patients correlating with hematologic response Initial results demonstrate a favorable safety profile – no dose limiting toxicit

Late-breaking oral presentation will highlight new data from a trial of INCA033989, an anti-mutant calreticulin (mutCALR)-directed monoclonal antibody, in patients with essential thrombocythemia (ET) Incyte to host an in-person analyst and investor event highlighting the mutCALR data at EHA on Sunday, June 15, 2025, from 6:00 - 7:30 a.m. EDT (12:00 - 1:30 p.m. CEST) Incyte (NASDAQ:INCY) today announced that data from numerous programs in its hematology/oncology portfolio will be presented at the 2025 European Hematology Association (EHA) congress, held June 12 – 15, 2025, in Milan. "We're looking forward to presenting new data from across our hematology/oncology portfolio at the 20

– Total revenues of $1,053 million in the first quarter (Q1'25) (+20% Y/Y); total product revenues of $922 million in Q1'25 (+26%Y/Y) – Jakafi® (ruxolitinib) net product revenues of $709 million in Q1'25 (+24% Y/Y); increasing full year 2025 Jakafi guidance to a new range of $2,950 - $3,000 million from $2,925 - $2,975 million – Opzelura® (ruxolitinib) cream net product revenues of $119 million in Q1'25 (+38% Y/Y) – Niktimvo™ (axatilimab-csfr) net product revenues of $14 million in the first two months of U.S. launch demonstrating strong commercial execution and high patient need – New, 18-week data from ongoing Phase 3 study of povorcitinib in hidradenitis suppurativa (HS) demonstrates

Incyte (NASDAQ:INCY) announced today that it has scheduled its first quarter financial results conference call and webcast for 8:00 a.m. ET on Tuesday, April 29, 2025. The schedule for the press release and conference call/webcast is as follows: Q1 2025 Press Release: April 29, 2025 at 7:00 a.m. ET Q1 2025 Conference Call: April 29, 2025 at 8:00 a.m. ET Domestic Dial-In Number: 877-407-3042 International Dial-In Number: 201-389-0864 Conference ID Number: 13753168 If you are unable to participate, a replay of the conference call will be available for thirty days. The replay dial-in number for the U.S. is 877-660-6853 and the dial-in number for international callers is 201-612-74

- Statistically significant results for primary endpoints in both STOP-HS1 and STOP-HS2 Phase 3 studies for both doses tested - Favorable safety profile, with no safety concerns - Data will support planned regulatory submission for povorcitinib in hidradenitis suppurativa (HS) worldwide - Incyte to hold an analyst and investor call on Monday, March 17, 2025 from 8:00-9:00 a.m. ET Incyte (NASDAQ:INCY) today announced positive topline results from its pivotal Phase 3 STOP-HS clinical trial program evaluating the safety and efficacy of povorcitinib (INCB054707), an oral small-molecule JAK1 inhibitor, in adult patients (≥18 years) with moderate to severe hidradenitis suppurativa (HS). Both

– Total revenues of $1.2 billion (+16% Y/Y) in the fourth quarter 2024 and $4.2 billion (+15% Y/Y) for the full year 2024 – Jakafi® (ruxolitinib) net revenues of $773 million (+11% Y/Y) in the fourth quarter 2024 and $2.8 billion (+8% Y/Y) for the full year 2024; Jakafi net revenues guidance range of $2,925 - $2,975 million for the full year 2025 – Opzelura® (ruxolitinib) cream net revenues of $162 million (+48% Y/Y) in the fourth quarter 2024 and $508 million (+50% Y/Y) for the full year 2024; Opzelura net revenues guidance range of $630 - $670 million for the full year 2025 – Ruxolitinib extended-release (XR) has met the bioequivalence criteria set by the FDA; these data are anticip

Incyte (NASDAQ:INCY) announced today that it has scheduled its fourth quarter and year-end 2024 financial results conference call and webcast for 8:00 a.m. ET on Monday, February 10, 2025. The schedule for the press release and conference call/webcast is as follows: • Q4 & YE 2024 Press Release: February 10, 2025 at 7:00 a.m. ET • Q4 & YE 2024 Conference Call: February 10, 2025 at 8:00 a.m. ET • Domestic Dial-In Number: 877-407-3042 • International Dial-In Number: 201-389-0864 • Conference ID Number: 13751174 If you are unable to participate, a replay of the conference call will be available for thirty days. The repl

- Twenty presentations, including late-breaking, oral and poster presentations, highlight advances across seven of the company's medicines - Late-breaking data presentation at ASH will feature results from the Phase 3 inMIND study evaluating tafasitamab in follicular lymphoma (FL); data to be highlighted during ASH press program - Incyte to host virtual analyst and investor event on Thursday, December 12, 2024, from 4:00-5:00 p.m. ET to discuss key data presentations from ASH Incyte (NASDAQ:INCY) today announced that the Company will present new data from across its oncology portfolio at the 2024 American Society of Hematology (ASH) Annual Meeting in San Diego. "These data illustrat

Total revenues of $1,138 million in the third quarter (Q3'24) (+24% Y/Y) Jakafi® (ruxolitinib) net product revenues of $741 million in Q3'24 (+16% Y/Y); raising full year 2024 Jakafi guidance to a new range of $2,740 - $2,770 million Opzelura® (ruxolitinib) cream net product revenues of $139 million in Q3'24 (+52% Y/Y); launch momentum continues in the U.S. supported by reimbursement expansion in Europe Niktimvo™ (axatilimab-csfr) approved by FDA for the treatment of chronic graft-versus-host disease after failure of at least two prior lines of systemic therapy in adult and pediatric patients Regulatory and development progress with supplemental New Drug Application (sNDA) for ruxo

Incyte (NASDAQ:INCY) announced today that it has scheduled its third quarter financial results conference call and webcast for 8:00 a.m. ET on Tuesday, October 29, 2024. The schedule for the press release and conference call/webcast is as follows: • Q3 2024 Press Release: October 29, 2024 at 7:00 a.m. ET • Q3 2024 Conference Call: October 29, 2024 at 8:00 a.m. ET • Domestic Dial-In Number: 877-407-3042 • International Dial-In Number: 201-389-0864 • Conference ID Number: 13749146 If you are unable to participate, a replay of the conference call will be available for thirty days. The replay dial-in number for the U.S. is 877-660-6853 and the dial-in

New antitumor response data from a range of doses and regimens unveiled today at Incyte investor event These results build upon safety and tolerability data presented earlier today during a mini-oral presentation at the European Society of Medical Oncology (ESMO) Congress 2024 Findings support the initiation of a pivotal trial in ovarian cancer, expected to begin in 2025; additional plans to evaluate INCB123667 in combination with other treatments are underway Incyte (NASDAQ:INCY) today announced new early clinical data for INCB123667, a highly selective, potential first-in-class CDK2 inhibitor, in patients with advanced solid tumors. The trial results, presented during a mini-oral p

- Presidential Symposium to feature Phase 3 retifanlimab (Zynyz®) results in squamous cell anal carcinoma (SCAC); filing of supplemental Biologics License Application (sBLA) in SCAC planned by year end 2024 - Mini oral presentation to highlight initial Phase 1 data from potential first-in-class CDK2 inhibitor program in patients with CCNE1 ovarian and other advanced cancers - Incyte to host an in-person analyst and investor event to review key data at ESMO, including new results from a later CDK2 data cut-off, on Saturday, September 14, 2024, from 1:00-2:30 p.m. ET (7:00-8:30 p.m. CEST) Incyte (NASDAQ:INCY) today announced that the Company will present key data from its oncology portf

Niktimvo™ (axatilimab-csfr) is the first approved anti-CSF-1R antibody targeting the drivers of inflammation and fibrosis seen in chronic GVHD Pivotal data from the AGAVE-201 study supporting the approval show treatment with Niktimvo resulted in durable responses across all organs studied and patient subgroups Syndax conference call and webcast scheduled for today at 6:00 p.m. ET Incyte (NASDAQ:INCY) and Syndax Pharmaceuticals (NASDAQ:SNDX) today announced that the U.S. Food and Drug Administration (FDA) has approved Niktimvo™ (axatilimab-csfr), an anti-CSF-1R antibody, for the treatment of chronic graft-versus-host disease (GVHD) after failure of at least two prior lines of syste

– Total revenues of $1,044 million in the second quarter (Q2'24) (+9% Y/Y) – Jakafi® (ruxolitinib) net product revenues of $706 million in Q2'24 (+3% Y/Y), total patients increased +7% Y/Y; raising the bottom end of full year 2024 guidance to a new range of $2,710 - $2,750 million – Opzelura® (ruxolitinib) net product revenues of $122 million in Q2'24 (+52% Y/Y); continued uptake in atopic dermatitis (AD) and vitiligo in the U.S.; launch momentum and reimbursement expansion in vitiligo in Europe – Incyte announces increased R&D focus on innovative high impact clinical programs; acquisition of Escient Pharmaceuticals completed – $2.0 billion share repurchase completed, underscoring c

Incyte (NASDAQ:INCY) announced today that it has scheduled its second quarter financial results conference call and webcast for 8:00 a.m. ET on Tuesday, July 30, 2024. The schedule for the press release and conference call/webcast is as follows: Q2 2024 Press Release: July 30, 2024 at 7:00 a.m. ET Q2 2024 Conference Call: July 30, 2024 at 8:00 a.m. ET Domestic Dial-In Number: 877-407-3042 International Dial-In Number: 201-389-0864 Conference ID Number: 13747471 If you are unable to participate, a replay of the conference call will be available for thirty days. The replay dial-in number for the U.S. is 877-660-6853 and the dial-in number for international callers is 201-6

– Total revenues of $881 million in the first quarter (Q1'24) (+9% Y/Y) – Jakafi® (ruxolitinib) net product revenues of $572 million in Q1'24, total paid patients increased +5% Y/Y; reiterating full year 2024 guidance of $2,690 - $2,750 million – Opzelura® (ruxolitinib) net product revenues of $86 million (+52% Y/Y) in Q1'24; continued uptake in atopic dermatitis (AD) and vitiligo – Incyte to acquire Escient Pharmaceuticals and its pipeline of first-in-class oral MRGPR antagonists with the potential to treat multiple mast cell-mediated diseases Conference Call and Webcast Scheduled Today at 8:00 a.m. ET Incyte (NASDAQ:INCY) today reports 2024 first quarter financial results, and p

EP262, a first-in-class oral Mas-related G protein-coupled receptor X2 (MRGPRX2) antagonist with the potential to treat a broad range of inflammatory disorders, has demonstrated proof-of-mechanism in chronic inducible urticaria and is in a Phase 2 study for chronic spontaneous urticaria EP547 is a first-in-class oral MRGPRX4 antagonist with the potential to treat cholestatic pruritus and other conditions with severe pruritus Acquisition supports Incyte's portfolio strategy and complements its expanding R&D activities in Inflammation and Autoimmunity (IAI) Incyte analyst and investor call scheduled for April 23, 2024 at 8:00 a.m. ET Incyte (NASDAQ:INCY) and Escient Pharmaceutica

Incyte (NASDAQ:INCY) announced today that it has scheduled its first quarter financial results conference call and webcast for 8:00 a.m. ET on Tuesday, April 30, 2024. The schedule for the press release and conference call/webcast is as follows: • Q1 2024 Press Release: April 30, 2024 at 7:00 a.m. ET • Q1 2024 Conference Call: April 30, 2024 at 8:00 a.m. ET • Domestic Dial-In Number: 877-407-3042 • International Dial-In Number: 201-389-0864 • Conference ID Number: 13745743 If you are unable to participate, a replay of the conference call will be available for thirty days. The replay dial-in number for the U.S. is 877-660-6853 and the dial-in number for inter

Two late-breaking abstracts have been accepted for oral presentation, including randomized studies evaluating ruxolitinib cream (Opzelura®) in hidradenitis suppurativa and povorcitinib (INCB54707) in prurigo nodularis Analyst and investor event to discuss key data presentations scheduled for Monday, March 11, 2024 at 9:00 a.m. PT / 12:00 p.m. ET   Incyte (NASDAQ:INCY) today announced multiple abstracts featuring data from its dermatology portfolio will be presented at the upcoming 2024 American Academy of Dermatology (AAD) Annual Meeting, held March 8-12, 2024, in San Diego. "We are pleased to convene at this year's AAD Annual Meeting and share data, including two late-breaking p

Total FY'23 net product and royalty revenues of $3.7 billion (+14% Y/Y); total FY'23 net product revenues of $3.2 billion (+15% Y/Y) Jakafi® (ruxolitinib) net revenues of $2.6 billion (+8%) for FY'23; Jakafi net revenues guidance range of $2,690 - $2,750 million for FY 2024 Opzelura® (ruxolitinib) cream net revenues of $109 million in Q4'23 and $338 million for FY'23, driven by strong demand in atopic dermatitis and the successful launch in vitiligo Advancing high potential pipeline provides opportunity for over 10 new launches by 2030 Incyte to host an in-person and webcast investor event on Monday, March 11, 2024 from 9:00-10:30 a.m. PT to discuss key data presentations a

Incyte (NASDAQ:INCY) announced today that it has scheduled its fourth quarter and year-end 2023 financial results conference call and webcast for 8:00 a.m. ET on Tuesday, February 13, 2024. The schedule for the press release and conference call/webcast is as follows: Q4 & YE 2023 Press Release: February 13, 2024 at 7:00 a.m. ET Q4 & YE 2023 Conference Call: February 13, 2024 at 8:00 a.m. ET Domestic Dial-In Number: 877-407-3042 International Dial-In Number: 201-389-0864 Conference ID Number: 13744020 If you are unable to participate, a replay of the conference call will be available for thirty days. The replay dial-in number for the U.S. is 877-660-6853 and the dial-in n

Presentation underscores potential of several high-impact launches across Oncology and Inflammation & Autoimmunity to drive sustainable long-term growth Company announces new positive topline results from Phase 2 trial evaluating ruxolitinib cream (Opzelura®) in adults with hidradenitis suppurativa (HS) Overview of early pipeline, including preliminary results from Phase 1 study of INCB123667 (CDK2i), will also be presented Incyte (NASDAQ:INCY) will highlight growth opportunities and provide key updates across its investigational pipeline and commercial portfolio during a presentation today at 7:30 a.m. PT at the 42nd Annual J.P. Morgan Healthcare Conference in San Francisco. "A

– Sixteen oral presentations, as well as a plenary session and poster presentations, highlight new advances across eight of the Company's medicines – Plenary Scientific Session will feature the full data from AGAVE-201 evaluating axatilimab, an anti-CSFR-1R monoclonal antibody, in patients with chronic graft-versus-host disease (GVHD) – Incyte to host an in-person analyst and investor event on Monday, December 11, 2023 from 12:00-1:30 p.m. PT to discuss key data presentations at ASH Incyte (NASDAQ:INCY) today announced that more than 40 abstracts highlighting data from eight of its hematology and oncology products will be presented at the upcoming 65th American Society of Hematology A

– Total revenues of $919 million in the third quarter (Q3'23) (+12% Y/Y) – Jakafi® (ruxolitinib) net product revenues of $636 million (+3% Y/Y) in Q3'23, $1.9 billion (+8% Y/Y) YTD 2023, driven by growth in total patients across all indications; tightening full year 2023 guidance to a new range of $2.59 - $2.62 billion – Opzelura® (ruxolitinib) cream net product revenues of $92 million (+141% Y/Y) in Q3'23, $229 million YTD 2023; continued uptake in atopic dermatitis (AD) and vitiligo and enhanced payer coverage – Phase 2 study evaluating povorcitinib in prurigo nodularis (PN) met its primary endpoint Conference Call and Webcast Scheduled Today at 8:00 a.m. ET Incyte (NASDAQ:INCY)

Incyte (NASDAQ:INCY) announced today that it has scheduled its third quarter financial results conference call and webcast for 8:00 a.m. ET on Tuesday, October 31, 2023. The schedule for the press release and conference call/webcast is as follows: Q3 2023 Press Release: October 31, 2023 at 7:00 a.m. ET Q3 2023 Conference Call: October 31, 2023 at 8:00 a.m. ET Domestic Dial-In Number: 877-407-3042 International Dial-In Number: 201-389-0864 Conference ID Number: 13741786 If you are unable to participate, a replay of the conference call will be available for thirty days. The replay dial-in number for the U.S. is 877-660-6853 and the dial-in number for international callers

Total net product revenues of $827 million in the second quarter (Q2'23) (+25% Y/Y) Jakafi® (ruxolitinib) net product revenues of $682 million (+14% Y/Y) in Q2'23; raising the bottom end of full year guidance to a new range of $2.58 - $2.63 billion for FY 2023 Opzelura® (ruxolitinib) cream net product revenues of $80 million (+384% Y/Y) in Q2'23; continued uptake in atopic dermatitis (AD) and vitiligo Two pivotal studies in high potential programs met their primary endpoint: ruxolitinib cream in pediatric atopic dermatitis (TRuE-AD3) and axatilimab in chronic GVHD (AGAVE-201) Conference Call and Webcast Scheduled Today at 8:00 a.m. ET Incyte (NASDAQ:INCY) today reports 2023

– Trial met its primary endpoint across all cohorts with an overall response rate (ORR) of 74% at a dose of 0.3 mg/kg administered every two weeks – –  Data highlight durable response to treatment. At the 0.3 mg/kg dose, 60% of patients who responded to axatilimab were still responding at one year – –  Results continue to support axatilimab's promising safety and efficacy profile, and reinforce its potential as a first-in-class CSF-1R monoclonal antibody in chronic graft-versus-host disease (GVHD) – – Syndax and Incyte intend to file a Biologics License Application (BLA) by year-end 2023; full dataset to be presented at a future medical meeting – – Syndax to host conference call today at 8:3

Incyte (NASDAQ:INCY) announced today that it has scheduled its second quarter financial results conference call and webcast for 8:00 a.m. ET on Tuesday, August 1, 2023. The schedule for the press release and conference call/webcast is as follows: Q2 2023 Press Release: August 1, 2023 at 7:00 a.m. ET Q2 2023 Conference Call: August 1, 2023 at 8:00 a.m. ET Domestic Dial-In Number: 877-407-3042 International Dial-In Number: 201-389-0864 Conference ID Number: 13739925 If you are unable to participate, a replay of the conference call will be available for thirty days. The replay dial-in number for the U.S. is 877-660-6853 and the dial-in number for international callers is 20

– Total net product revenues of $693 million in Q1'23 (+14% Y/Y) – Jakafi® (ruxolitinib) net product revenues of $580 million (+7% Y/Y) in Q1'23; raising the bottom end of full year guidance to new range of $2.55 - $2.63 billion for FY 2023 – Opzelura® (ruxolitinib) cream approved as the first and only treatment for repigmentation of nonsegmental vitiligo in Europe; continued strong U.S. launch in atopic dermatitis and vitiligo – Multiple positive data readouts from dermatology portfolio at AAD and EHSF 2023 – Conference Call and Webcast Scheduled Today at 8:00 a.m. ET Incyte (NASDAQ:INCY) today reports 2023 first quarter financial results, and provides a status update on the Comp

Incyte (NASDAQ:INCY) announced today that it has scheduled its first quarter financial results conference call and webcast for 8:00 a.m. ET on Tuesday, May 2, 2023. The schedule for the press release and conference call/webcast is as follows: Q1 2023 Press Release: May 2, 2023 at 7:00 a.m. ET Q1 2023 Conference Call: May 2, 2023 at 8:00 a.m. ET Domestic Dial-In Number: 877-407-3042 International Dial-In Number: 201-389-0864 Conference ID Number: 13737924 If you are unable to participate, a replay of the conference call will be available for thirty days. The replay dial-in number for the U.S. is 877-660-6853 and the dial-in number for international callers is 201-612-741

Three late-breaking presentations in vitiligo highlight new long-term data from the Phase 3 TRuE-V trials for Opzelura® (ruxolitinib) cream and results from a Phase 2b study with povorcitinib (INCB54707), an oral JAK1 inhibitor Incyte to host an in-person analyst and investor event on Saturday, March 18, 2023, from 5:30-7:00 p.m. CT to discuss key vitiligo data presentations Incyte (NASDAQ:INCY) today announced that multiple abstracts featuring data from its dermatology portfolio will be presented at the upcoming 2023 American Academy of Dermatology (AAD) Annual Meeting, held March 17-21, 2023, in New Orleans. New data from the Phase 3 TRuE-V clinical trial program evaluating the dura

– Total FY'22 net product revenues grew 18% to $2.75 billion; total FY'22 revenues of $3.4 billion (+14% Y/Y) – Jakafi® (ruxolitinib) net revenues of $647 million (+9% Y/Y) in Q4'22 and $2.41 billion (+13%) in FY'22; Jakafi net revenues guidance range of $2.53 - $2.63 billion for FY 2023 – Opzelura™ (ruxolitinib) Cream net revenues of $61 million in Q4'22 and $129 million in FY'22, driven by strong demand in atopic dermatitis, a successful launch in vitiligo and broadening formulary access Conference Call and Webcast Scheduled Today at 8:00 a.m. ET Incyte (NASDAQ:INCY) today reports 2022 fourth quarter financial results, provides 2023 financial guidance and provides a status update on t

Incyte (NASDAQ:INCY) announced today that it has scheduled its fourth quarter and year-end 2022 financial results conference call and webcast for 8:00 a.m. ET on Tuesday, February 7, 2023. The schedule for the press release and conference call/webcast is as follows: Q4 & YE 2022 Press Release: February 7, 2023 at 7:00 a.m. ET Q4 & YE 2022 Conference Call: February 7, 2023 at 8:00 a.m. ET Domestic Dial-In Number: 877-407-3042 International Dial-In Number: 201-389-0864 Conference ID Number: 13735569 If you are unable to participate, a replay of the conference call will be available for thirty days. The replay dial-in number for the U.S. is 877-660-6853 and the dial-in number for

- Plenary Scientific Session to highlight Incyte-discovered novel anti-mutant CALR-targeted monoclonal antibody INCA033989 - Data from three of the Company's LIMBER studies evaluating ruxolitinib in combination with parsaclisib and its ALK2 and BET inhibitors to be presented - Incyte to host an in-person analyst and investor event on Sunday, December 11, 2022, from 8:00-9:30 p.m. CT to discuss key data presentations at ASH Incyte (NASDAQ:INCY) will present data from its oncology portfolio at the upcoming 64th American Society of Hematology Annual Meeting (ASH 2022), held December 10-13, 2022, in New Orleans and virtually. More than 50 abstracts featuring Incyte compounds will be presente

– Total net product revenues grew to $713 million (+20% Y/Y) as a result of strong Jakafi® (ruxolitinib) and Opzelura™ (ruxolitinib) cream net product revenues – Jakafi net product revenues of $620 million in Q3'22 (+13% Y/Y); raising the bottom end of full year guidance to a new range of $2.38 to $2.40 billion – Opzelura net product revenues of $38 million in Q3'22 driven by robust demand and broadening payer access; launch in vitiligo underway – Pipeline progresses with positive povorcitinib data in hidradenitis suppurativa at EADV, oral PD-L1 update at SITC and the pending acquisition of Villaris Therapeutics and auremolimab, a novel anti-IL-15Rβ mAb   Conference Call and Webcast Sch

Incyte (NASDAQ:INCY) announced today that it has scheduled its third quarter financial results conference call and webcast for 8:00 a.m. ET on Tuesday, November 1, 2022. The schedule for the press release and conference call/webcast is as follows: Q3 2022 Press Release: November 1, 2022 at 7:00 a.m. ET Q3 2022 Conference Call: November 1, 2022 at 8:00 a.m. ET Domestic Dial-In Number: 877-407-3042 International Dial-In Number: 201-389-0864 Conference ID Number: 13733379 If you are unable to participate, a replay of the conference call will be available for thirty days. The replay dial-in number for the U.S. is 877-660-6853 and the dial-in number for international callers is 201-

Total revenues increased 29% year-over-year (Y/Y) to $911 million; total product revenues of $664 million (+15% Y/Y) Jakafi® (ruxolitinib) net product revenues of $598 million in Q2'22 (+13% Y/Y) driven by volume growth; raising the bottom end of full year guidance to new range of $2.36 to $2.40 billion Opzelura™ (ruxolitinib) cream approved as first and only treatment for repigmentation of nonsegmental vitiligo in patients aged 12 and older; launch progressing in atopic dermatitis (AD) Multiple approvals including Olumiant® (baricitinib) as the first and only systemic treatment approved for alopecia areata in the U.S., Europe and Japan and Jakavi® (ruxolitinib) approved as the first

Opzelura is the first and only FDA-approved product for repigmentation in nonsegmental vitiligo Phase 3 data supporting the approval show treatment with Opzelura resulted in improvements in facial and total body repigmentation Fifty-two week data demonstrate continued improvements in repigmentation with longer duration of treatment Investor conference call and webcast scheduled for July 19, 2022, at 8:00 a.m. EDT Incyte (NASDAQ:INCY) today announced that the U.S. Food and Drug Administration (FDA) has approved Opzelura™ (ruxolitinib) cream 1.5% for the topical treatment of nonsegmental vitiligo in adult and pediatric patients 12 years of age and older. Opzelura is the first and

Incyte (NASDAQ:INCY) announced today that it has scheduled its second quarter financial results conference call and webcast for 8:00 a.m. ET on Tuesday, August 2, 2022. The schedule for the press release and conference call/webcast is as follows: • Q2 2022 Press Release:     August 2, 2022 at 7:00 a.m. ET • Q2 2022 Conference Call:     August 2, 2022 at 8:00 a.m. ET • Domestic Dial-In Number:     877-407-3042 • International Dial-In Number:     201-389-0864 • Conference ID Number:     13731520 If you are unable to participate, a replay of the conference call will be available for thirty days. The replay dial-in number

Added 16,423 New Subscribers in 4QFY22 4QFY22 Revenues Down 1.7% YoY to RMB297.2 Million ($46.9 Million) 4QFY22 Gross Profit Down 0.5% YoY to RMB255.2 Million ($40.3 Million) 4QFY22 Operating Income Down 4.1% YoY to RMB142.1 Million ($22.4 Million) 4QFY22 Non-GAAP Operating Income Down 4.1% YoY to RMB153.9 Million ($24.3 Million) HONG KONG, July 5, 2022 /PRNewswire/ -- Global Cord Blood Corporation (NYSE:CO) ("GCBC" or the "Company"), China's leading provider of cord blood collection, laboratory testing, hematopoietic stem cell processing and stem cell storage services, today announced its unaudited financial results for the fourth quarter and full year of fiscal 2022, ended March 31, 2022.

- Zenocutuzumab clinical abstract selected for oral presentation at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting- Company to host investor call on Sunday, June 5 at 6:00 p.m. CT- Clinical data update of petosemtamab (Peto) and MCLA-129 planned for second half of 2022 UTRECHT, The Netherlands and CAMBRIDGE, Mass., May 09, 2022 (GLOBE NEWSWIRE) -- Merus N.V. (NASDAQ:MRUS) ("Merus", the "Company," "we", or "our"), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics® and Triclonics®), today announced financial results for the first quarter that ended March 31, 2022, and provided a business update. "We continue t

Total product and royalty revenues of $728 million in Q1'22 (+20% Y/Y) Jakafi® (ruxolitinib) net product revenues of $544 million in Q1'22 (+17% Y/Y); raising the bottom end of full year guidance to new range of $2.33 to $2.40 billion Robust uptake of Opzelura™ (ruxolitinib) cream with over 38,000 new patients treated in the first quarter; meaningful progress with payers resulting in 146 million total lives now covered Positive 52-week data from the Phase 3 TRuE-V program evaluating ruxolitinib cream in patients with vitiligo presented at AAD 2022; ruxolitinib cream is currently under review in the U.S. and Europe    Conference Call and Webcast Scheduled Today at 8:00 a.m. EDT

Incyte (NASDAQ:INCY) announced today that it has scheduled its first quarter financial results conference call and webcast for 8:00 a.m. ET on Tuesday, May 3, 2022. The schedule for the press release and conference call/webcast is as follows:     • Q1 2022 Press Release: May 3, 2022 at 7:00 a.m. ET     • Q1 2022 Conference Call: May 3, 2022 at 8:00 a.m. ET     • Domestic Dial-In Number: 877-407-3042     • International Dial-In Number: 201-389-0864     • Conference ID Number: 13728884 If you are unable to participate, a replay of the conference call will be available for thirty days. The replay dial-in number for the U.S. is

Total product and royalty revenues of $813 million (+20%) in Q4'21 and $2.891 billion (+17%) in FY'21 Jakafi® (ruxolitinib) net product revenues of $592 million (+15%) in Q4'21 and $2.135 billion (+10%) in FY'21; Jakafi guidance range of $2.3 to $2.4 billion for 2022 Successful U.S. launch of Opzelura™ (ruxolitinib) cream in atopic dermatitis with nearly 19,000 patients treated from launch (October 11th) through the end of the year Vitiligo is the next substantial growth opportunity for ruxolitinib cream – under Priority Review in the U.S. and under review in Europe Conference Call and Webcast Scheduled Today at 8:00 a.m. EST Incyte (NASDAQ:INCY) today reports 2021 fourth quarter

Incyte (NASDAQ:INCY) announced today that it has scheduled its fourth quarter and year-end 2021 financial results conference call and webcast for 8:00 a.m. ET on Tuesday, February 8, 2022. The schedule for the press release and conference call/webcast is as follows: • Q4 & YE 2021 Press Release: February 8, 2022 at 7:00 a.m. ET • Q4 & YE 2021 Conference Call: February 8, 2022 at 8:00 a.m. ET • Domestic Dial-In Number: 877-407-3042 • International Dial-In Number: 201-389-0864 • Conference ID Number: 13726298 If you are unable to participate, a replay of the conference call will be available for ninety days. The replay dial-in number for the U.S. is

Investor conference call and webcast scheduled for November 13, 2021, at 6:30 p.m. ET Incyte (NASDAQ:INCY) today announced that multiple abstracts highlighting data from its oncology portfolio will be presented at the Society for Immunotherapy of Cancer's (SITC) 36th Annual Meeting, held from November 10-14, 2021 in Washington, D.C and virtually. "We look forward to presenting data from multiple programs within Incyte's immuno-oncology portfolio at this year's SITC conference," said Lance Leopold, M.D., Group Vice President, Immuno-Oncology, Incyte. "Data being presented from the retifanlimab POD1UM clinical program, including a late-breaking poster presentation highlighting results from

Incyte (NASDAQ:INCY) announced today that it has scheduled its third quarter financial results conference call and webcast for 8:00 a.m. ET on Tuesday, November 2, 2021. The schedule for the press release and conference call/webcast is as follows: • Q3 2021 Press Release: November 2, 2021 at 7:00 a.m. ET • Q3 2021 Conference Call: November 2, 2021 at 8:00 a.m. ET • Domestic Dial-In Number: 877-407-3042 • International Dial-In Number: 201-389-0864 • Conference ID Number: 13724199 If you are unable to participate, a replay of the conference call will be available for thirty days. The replay dial-in number for the U.S. is 877-660-6853

WALTHAM, Mass. and WILMINGTON, Del., Sept. 27, 2021 /PRNewswire/ -- Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) and Incyte (NASDAQ:INCY) announced today that they have entered into an exclusive worldwide collaboration and license agreement to develop and commercialize axatilimab, Syndax's anti-CSF-1R monoclonal antibody. "This partnership has the potential to significantly expand and maximize the axatilimab program across multiple lines of treatment in chronic graft-versus-host Disease (cGVHD), as well as additional indications in which the monocyte-macrophage lineage plays a vital role in the fibrotic disease process, such as idiopathic pulmonary fibrosis (IPF)," said Briggs W. Morrison, M.D

- Opzelura is the first and only topical Janus kinase (JAK) inhibitor approved in the United States - In Phase 3 studies, Opzelura significantly reduced the skin inflammation and itch associated with AD - Investor conference call and webcast scheduled for September 22, 2021, at 8:00 a.m. ET Incyte (NASDAQ:INCY) today announced that the U.S. Food and Drug Administration (FDA) has approved Opzelura™ (ruxolitinib) cream for the short-term and non-continuous chronic treatment of mild to moderate atopic dermatitis (AD) in non-immunocompromised patients 12 years of age and older whose disease is not adequately controlled with topical prescription therapies, or when those therapies are not advi